Skip to main content


With mirrored RNA against highly aggressive brain tumors

Glioblastomas are particularly aggressive brain tumors that quickly grow into healthy brain tissue. As the tumors cannot usually be completely removed surgically, the prognosis for glioblastoma patients is very poor. Standard therapy - consisting of a combination of surgery, radiotherapy and chemotherapy - does not promise a cure. The search is therefore on for successful treatment options. Scientists at the University Medical Center Mannheim (UMM), the DKFZ-Hector Cancer Institute at the UMM and the University Hospital Bonn (UKB) led by Frank Giordano are researching a new therapy with a novel class of drugs consisting of mirrored RNA polymers, so-called Spiegelmers, which are designed to block the regeneration of glioblastoma.


Read more

Lisa-Marie Rieckmann, DKFZ-Hector Krebsinstitut an der UMM

Circulating tumor cells provide detailed insights into cancer heterogeneity

08/05/2024 | by Koh

An improved method for isolating circulating tumor cells paves the way for tailor-made therapies in personalized oncology: in a recent study, study leaders Sonja Loges and Melanie Janning from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim show that it is possible to obtain sufficient circulating tumor cells using a blood cell enrichment technique (diagnostic leukapheresis) to comprehensively analyze the tumor and its heterogeneity.

Read more

Adobe Stock

Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

03/05/2023 | by Koh

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system. In this way, the body presumably curbs destructive immune reactions. Researchers from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors (ICI) in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. Interventions in this mechanism could potentially improve the efficacy of these cellular cancer immunotherapies.


ERC Advanced Grants for Hannah Monyer and Michael Platten

11/04/2024 | by Koh

The European Research Council (ERC) supports visionary, ground-breaking research projects with its "Advanced Grants". This year, the Council awarded the prestigious funding to two researchers at the German Cancer Research Center (DKFZ): Neuroscientist Hannah Monyer, DKFZ and Heidelberg University Hospital, wants to find new explanations for the development of neurodegenerative diseases. Neurologist Michael Platten, DKFZ and University Medical Center Mannheim, will use the ERC funding to develop and test personalized cellular immunotherapies against malignant brain tumors.


» RTL: Prof. Dr. Dr. Loges über Krebsprävention
Prof. Dr. Dr. Sonja Loges war im RTL-Mittagsjournal Punkt 12 zu Gast. Der ausführliche Beitrag zum Thema Krebsprävention mit Antworten auf Zuschauerfragen und mehreren Infoclips beginnt ab 01:18:30.